Berlin, 30 April 2008. On the occasion of its tenth anniversary, the Berlin-based company Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) announced that it will be offering 25 travel grants for the annual congresses of the European Association of Nuclear Medicine (EANM). These grants are designed to support young scientists and doctoral students throughout Europe who seek to present the results of their work directly to larger audiences over the next five years. The winners will be selected together with EANM, starting with the annual European congress in Munich in October of 2008.
Berlin, 23 April 2008. On the occasion of its tenth anniversary, the Berlin-based company Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE 0005659700) announced that it will be offering 25 travel grants for the annual congresses of the European Association of Nuclear Medicine (EANM). These grants are designed to support young scientists and doctoral students throughout Europe who seek to present the results of their work directly to larger audiences over the next five years. The winners will be selected together with EANM, starting with the annual European congress in Munich in October of 2008.
The Group sees considerable potential in the further development of nuclear medical diagnostic techniques, especially based on more widespread use of so-called hybrid cameras. These cameras combine different imaging processes - including Positron Emission Topography, a nuclear medical method also known as PET scans. The quality and information content of the images are taking on completely new dimensions and are enabling the development of new treatments and operational control processes.
Eckert & Ziegler is supporting greater use of hybrid systems by expanding its production sites for radioactive contrast agents, and by developing automated synthesis modules in which scientists can produce new diagnostic substances with the requisite pharmaceutical quality. The Group, which currently has around 450 employees and expects sales of 70 million euros in 2008, is one of the world's largest providers of isotope component technology for radiation therapy and nuclear medicine.
The Board of Directors